Abstracts tagged "Patient reported outcomes"

Abstract Number: 1644 • ACR Convergence 2021
Storytelling of Young Adults with Chronic Rheumatologic Illnesses: A Pilot Study
Aviya Lanis¹, Emilee Tu², Malki Peskin³, Maryann Melendez¹, Gabriel Tarshish⁴, Alisha Akinsete⁵, Alicia Hoffman¹, Kathleen Kenney-Riley⁶, Tamar Rubinstein⁷ and Dawn Wahezi¹, ¹Children's Hospital at Montefiore, Bronx, NY, ²Albert Einstein School of Medicine, Bronx, NY, ³Montefiore, Bronx, NY, ⁴Children's Hospital at Montefiore, New York, NY, ⁵Montefiore, Wayne, NJ, ⁶Mercy College, Dobbs Ferry, NY, ⁷Albert Einstein College of Medicine, White Plains, NY
Background/Purpose: Storytelling is a universal form of communication that allows expression of experiences. Narrative medicine can be described as a subset of storytelling in which…
Abstract Number: 0112 • ACR Convergence 2021
A Randomized Trial Showing No Differences in Patient Satisfaction with Telemedicine Delivered by Phone or Video During COVID-19 in Rheumatology and Other Medical Specialty Clinics
Maria I. Danila¹, Dongmei Sun², Lesley Jackson¹, Gary Cutter¹, Elizabeth Jackson¹, Eric Ford¹, Erin DeLaney¹, Amy Mudano¹, Jeffrey Foster¹, Giovanna Rosas¹, Jeffrey Curtis³ and Kenneth Saag¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The COVID-19 pandemic has led to a significant shift to home-based telemedicine including video and phone-only visits in many medical specialties. However, patients may…
Abstract Number: 0400 • ACR Convergence 2021
Item Development for the Assessment of Systemic Sclerosis-associated Raynaud’s Phenomenon (ASRAP) Questionnaire
John Pauling¹, Lesley Ann Saketkoo², Dinesh Khanna³, Christopher Denton⁴, Tracy Frech⁵, Ariane Herrick⁶, Laura Hummers⁷, Ami Shah⁸ and Robyn Domsic⁹, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University Medical Center - Comprehensive Pulmonary Hypertension Center, New Orleans, LA, ³University of Michigan, Ann Arbor, MI, ⁴University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁵University of Utah, Salt Lake City, UT, ⁶University of Manchester, Salford, United Kingdom, ⁷Johns Hopkins Univerisity, Baltimore, MD, ⁸Johns Hopkins Rheumatology, Baltimore, MD, ⁹University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The episodic and uniquely personalised nature of Raynaud’s phenomenon (RP) has led to reliance upon self-report to capture how patients ‘feel’ and ‘function’. Existing…
Abstract Number: 0739 • ACR Convergence 2021
Contextual Factors Should Complete the Assessment of Functioning in Patients with Axial Spondyloarthritis (axSpA)
Uta Kiltz¹, Eerik Ahomaa², Björn Buehring¹, Xenofon Baraliakos¹, David Kiefer¹, Jaclyn-Dalisay Leicht¹ and Jürgen Braun¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²St. Franziskus-Hospital, Department of Orthopedic Surgery, Cologne, Germany
Background/Purpose: Functioning of axSpA patients (pat.) is influenced by many factors, but how contextual factors influence functioning isn’t well studied. According to the International Classification…
Abstract Number: 0762 • ACR Convergence 2021
Validity of the Musculoskeletal Health Questionnaire: Real World Analysis of Data Collection via an Electronic Patient Reported Outcome Platform
Amy Boalch¹, Sam Norton¹, Sophia Steer², Nicky Wilson² and James Galloway³, ¹King's College London, London, United Kingdom, ²King's College Hospital, London, United Kingdom, ³Kings College London, London, United Kingdom
Background/Purpose: The Musculoskeletal Health Questionnaire (MSK-HQ) is a patient reported outcome measure (PROM) validated to assess disease outcomes in patients with MSK disorders. This study…
Abstract Number: 0860 • ACR Convergence 2021
Associations Between Tricarboxylic Acid Cycle Plasma Metabolites and Fatigue Phenotypes in Black Females with Systemic Lupus Erythematosus: An Untargeted Metabolomics Analysis
Laura Kimble¹, Arezou Khosroshahi¹, Glenna Brewster¹, Nicole Carlson¹, Ronald Eldridge¹ and Elizabeth Corwin², ¹Emory University, Atlanta, GA, ²Columbia University, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) occurs predominantly in women and Black women have disproportionately poorer health outcomes across the trajectory of their disease compared to…
Abstract Number: 1214 • ACR Convergence 2021
Examining the Relationship Between Shared Epitope, ACPA Seropositivity, and Real-World Drug Effectiveness in Patients with Rheumatoid Arthritis
Kristin Wipfler¹, Joshua Baker², Harlan Sayles³, Xue Han⁴, Sang Hee Park⁴, Keith Wittstock⁴, Ted Mikuls³ and Kaleb Michaud³, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³University of Nebraska Medical Center, Omaha, NE, ⁴Bristol Myers Squibb, Princeton, NJ
Background/Purpose: The shared epitope (SE) is an amino acid sequence motif coded by several HLA-DRB1 alleles that are overrepresented among people with rheumatoid arthritis (RA).…
Abstract Number: 1350 • ACR Convergence 2021
Sustained Improvement in Physical Function, Disease Impact and Health-Related Quality of Life in Patients with Psoriatic Arthritis Treated with Bimekizumab: 3-Year Results from a Phase 2b Open-Label Extension Study
Laure Gossec¹, Akihiko Asahina², Alice Gottlieb³, Laura Coates⁴, Barbara Ink⁵, Deepak Assudani⁶, Jason Coarse⁷, Scarlett Hellot⁸, Jason Eells⁶ and Philip Mease⁹, ¹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ²Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁵UCB Celltech, Slough, UK, Slough, United Kingdom, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Raleigh, NC, ⁸UCB Pharma, Colombes, France, ⁹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17F and IL-17A, and has demonstrated clinical improvements in joint and skin…
Abstract Number: 1652 • ACR Convergence 2021
Symptom Burden in Anti-citrullinated Protein Antibody Positive Individuals At-risk for Rheumatoid Arthritis Is Changing over Time and Comparable to Patients with Early Rheumatoid Arthritis
Paul Studenic¹, Alexandra Circiumaru², Daniel Aletaha³, Katerina Chatzidionysiou⁴, Anca Catrina⁵ and Aase Haj Hensvold⁶, ¹Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, ²Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden, ³Medical University Vienna, Vienna, Austria, ⁴Karolinska Institute, Division of Rheumatology; & Karolinska University Hospital, Rheumatology Unit, Stockholm, Sweden, ⁵Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Karolinska Institutet, Division for Rheumatology; & Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden
Background/Purpose: Symptom burden in individuals at risk for developing rheumatoid arthritis (RA) - positive for anti-citrullinated peptide antibodies (ACPA) and musculoskeletal complaints - has not…
Abstract Number: 0124 • ACR Convergence 2021
Nurse-supported Web-based Cognitive Behavioral Therapy for Chronic Musculoskeletal Pain: An Effectiveness Trial
Rami Diab¹, Rebecca Bomar², Christina Rinaldi², Claudia Campos², Sebastian Kaplan² and Dennis Ang³, ¹Wake Forest Baptist Health/Wake Forest School of Medicine, Winston-Salem, NC, ²Wake Forest School of Medicine / Wake Forest University Baptist Medical Center, Winston-Salem, NC, ³Wake Forest School of Medicine, Winston-Salem, NC
Background/Purpose: Pain accounts for greater than 40% of all symptom-related outpatient visits totaling over 100 million outpatient encounters worth hundreds of billions of dollars annually…
Abstract Number: 0401 • ACR Convergence 2021
Item Reduction for the Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaire Using Data from the International Multicentre ASRAP Validation Study
John Pauling¹, Lan Yu², Christopher Denton³, Tracy Frech⁴, Ariane Herrick⁵, Laura Hummers⁶, Lesley Ann Saketkoo⁷, Ami Shah⁸, Dinesh Khanna⁹ and Robyn Domsic², ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University of Pittsburgh, Pittsburgh, PA, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁴University of Utah, Salt Lake City, UT, ⁵University of Manchester, Salford, United Kingdom, ⁶Johns Hopkins Univerisity, Baltimore, MD, ⁷University Medical Center - Comprehensive Pulmonary Hypertension Center, New Orleans, LA, ⁸Johns Hopkins Rheumatology, Baltimore, MD, ⁹University of Michigan, Ann Arbor, MI
Background/Purpose: The Assessment of Systemic sclerosis-associated RAynaud’s Phenomenon (ASRAP) questionnaire is a novel patient-reported outcome (PRO) instrument devised to assess the severity and impact of…
Abstract Number: 0741 • ACR Convergence 2021
Assessing the Relationship of Patient Global Assessment of Disease Activity and Health Related Quality of Life by SF-36 with Other Patient-Reported Outcomes in Rheumatoid Arthritis: Post Hoc Analyses of Data from Phase 3 Trials of Baricitinib
Vibeke Strand¹, Anthony Sebba², Savannah Scardo³, Amanda Quebe⁴, Liliana Zaremba-Pechmann⁵ and Peter C Taylor⁶, ¹Stanford University, Portola Valley, CA, ²Division of Rheumatology, University of South Florida, Tampa, FL, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Indanapolis, IN, ⁵HaaPACS, Schriesheim, Germany, ⁶University of Oxford, Oxford, United Kingdom
Background/Purpose: Improvements in patient-reported outcomes (PROs) were demonstrated in randomized controlled trials (RCTs) of baricitinib (BARI), an oral Janus kinase (JAK)1/JAK2 inhibitor, for the treatment…
Abstract Number: 0763 • ACR Convergence 2021
What Does the Patient Well-Being Vas Tell Us When the Physician Global Assessmentscore Is Zero? Analysis of a Large Multinational Dataset
Francesca Ridella¹, Roberta Naddei², Maddalena Spelta², Cristina N. Herrera³, Clara Malagon⁴, Olga Arguedas⁵, Amparo Ibanez Estrella⁶, Nicola Ruperto⁷, Angelo Ravelli⁸ and Alessandro Consolaro⁹, ¹Università degli Studi di Genova Genoa, Italy, Genova, Italy, ²Istituto Giannina Gaslini, Genova, Italy, ³Hospital de Ninos Roberto Gilbert Elizalde, Rheumatology, Guayaquil, Ecuador, Paediatric Rheumatology International Trials Organisation (PRINTO), Guayaquil, Ecuador, ⁴Hospital Universitario Simon Bolivar, Clinica infantil Colsubsidio, Facultad de Medicina, Post Grado Reumatologia Pediatrica, Universidad El Bosque, Bogota, Colombia, Paediatric Rheumatology International Trials Organisation (PRINTO), Bogotà, Colombia, ⁵Hospital Nacional de Ninos Dr Carlos Saenz Herrera, Servicio de Immunologia y Reumatologia pediatrica, San Josè, Costa Rica, Paediatric Rheumatology International Trials Organisation (PRINTO), San Josè, Costa Rica, ⁶National Institute Salud del Nino, Rheumatology Service, Brena, Lima, Peru, Paediatric Rheumatology International Trials Organisation (PRINTO), Lima, Peru, ⁷Istituto Giannina Gaslini, Paediatric Rheumatology International Trials Organisation (PRINTO), Genova, Italy, ⁸Istituto Giannina Gaslini, Genoa, Italy, ⁹Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy
Background/Purpose: Parent- and child-reported outcomes (PCROs) reflect the parent and child perception of rheumatic disease course and effectiveness of therapeutic interventions. Among PCROs for the…
Abstract Number: 0869 • ACR Convergence 2021
Comparison of Two Frailty Definitions in Women with Systemic Lupus Erythematosus
Sarah Lieber¹, Musarrat Nahid², Alexandra Legge³, Mangala Rajan², Robyn Lipschultz¹, Myriam Lin¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Dalhousie University, Halifax, NS, Canada
Background/Purpose: Frailty is a novel risk factor for adverse health outcomes in systemic lupus erythematosus (SLE). Multiple definitions of frailty, including the Fried definition (FD),…
Abstract Number: 1223 • ACR Convergence 2021
A Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease-Modifying Therapies: 6-Month Effectiveness and Patient Reported Outcome Data from the European Cohort
Gerd Burmester¹, Bruno Fautrel², Rieke Alten³, Marco Matucci-Cerinic⁴, Jean hugues Salmon⁵, Thorsten Holzkaemper⁶, Inmaculada de la Torre⁷, Pedro Lopez-Romero⁸, Walid Fakhouri⁸ and Anja Gentzel-Jorczyk⁸, ¹Charité University Medicine Berlin, Berlin, Germany, ²Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ³Schlosspark-Klinik University, Berlin, Germany, ⁴University of Florence, Florence, Italy, ⁵Rheumatology, CHU Maison blanche, Reims, Reims, France, ⁶Eli Lilly and Company, Bad Homburg, Germany, ⁷Eli Lilly and Company, Alcobendas, Spain, ⁸Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (BARI) is a JAK1/2 inhibitor approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) and the treatment of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.